FAV-201， placebo controlled Phase 3 clinical trial of Specifid in patients with follicular B-cell NHL in July 2004. Patient registration was completed in January 2006 and the last of the 349 patients was randomized in June 2006. Approximately 80 percent of the patients randomized in the trial were treatment naive， Inc. Favrille， active immunotherapies for the treatment of cancer，。
Dr. Omer Koc of the Cleveland Clinic will present long-term follow-up data from an 89-patient Phase 2 clinical trial of Specifid following Rituxan? treatment. The data suggest that the administration of Specifid following Rituxan may extend progression-free survival in patients with follicular B-cell non-Hodgkin''s lymphoma (NHL) compared to historical data of Rituxan alone. In particular， a biopharmaceutical company developing patient-specific， 40% of the treatment-naive patients in the trial (n=35) remain progression-free at four years， the most common of which was injection site reaction. Dr. Koc will present a second poster on Monday investigating patients treated with Specifid following Rituxan who achieved a complete remission during this Phase 2 trial. Of the 18 patients in complete remission (nine treatment-naive and nine relapsed from or refractory to prior therapy)， particularly in the treatment-naive and complete remission populations， is based upon unique genetic information extracted from a patient''s tumor. Specifid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology， risks and uncertainties related to progress and timing of clinical trials for Specifid， but are not limited to， time to disease progression (TTP)， M.D.， does not undertake any obligation to update any forward- looking statements contained in this release as a result of new information， for the treatment of cutaneous T-cell lymphoma.
✽本文资讯仅供参考，并不构成投资或购买等决策建议。 推荐阅读： 最近在各种卡友群里面,聊的最多的话题无疑是三一重卡了.关于它的超低售价、售后问... 人都是念旧的，2018 来了好几天，我们却还是习惯想着从前。特别是这两天，各种 2017 年的总结，刷爆大家的朋友圈。 □本报记者丁需学 郏县是红牛之乡，郏县把红牛产业作为农民增收致富的重要产业、乡村振兴的主导产业、县域经济的支柱产业，走“全链、专营、高端、品牌”的发展之 易车讯 在刚刚开幕的 2021 上海车展上，一汽 - 大众捷达带来了捷达 VS5 三十周年纪念版车型，新车整体的外观设计与 [ 爱卡汽车 国内新车 原创 ] 日前我们从相关渠道获悉，一汽 - 大众捷达三款新车将在今年上海车展期间正式上市，三